ClinicalTrials.gg
Enrolling by invitationNCT06860659Updated Mar 6, 2025

Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient with Moderate to Severe Dry Eye

A Phase 4 interventional study of 0.28% Sodium Hyaluronate , preservative free eye drops and 0.18% Sodium Hyaluronate , preservative free eye drops in Dry Eye Disease (DED), Tear Break-Up Time and Tear Disorder, sponsored by Department of Medical Services Ministry of Public Health of Thailand. Enrolling by invitation at 1 site in Thailand. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Department of Medical Services Ministry of Public Health of Thailand · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 5 months after the study started (first participant enrolled Sep 2024, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Dry Eye Syndromes with a site in Thailand — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Thailand.

Started
2024
the only one that year
Phase 4
4 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Department of Medical Services Ministry of Public Health of Thailand

Among the 10 studies in Dry Eye Syndromes with a site in Thailand, this one is the only one that started in 2024, is one of 4 in phase 4, and was the 10th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 10 studies in Dry Eye Syndromes with a site in Thailand is open now.

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Dry Eye Syndromes with a site in Thailand, or all of them as a file.
02

Study summary

This study aimed to evaluate the efficacy and safety of 0.28% preservative-free SH and 0.18% SH eye drops in patients with dry eye disease. Subjects diagnosed with dry eye disease and meeting the inclusion criteria (Ocular Surface Disease Index (OSDI) score ≥ 23, Fluorescein Tear Breakup Time (TBUT) \< 7 seconds were randomized into two groups. Group 1 (42 eyes) received 0.28% SH, and Group 2 (42 eyes) received 0.18% SH, both administered by a nurse. Measurements included tear osmolarity (TearLAB) before instillation and at 0,30 and 60 minutes post-instillation, recorded by a TearLAB specialist. Ophthalmologists assessed TBUT, ocular surface staining (Oxford grading scale), and the Schirmer I test before instillation and evaluated adverse reactions up to 60 minutes post-instillation. Subjects continued treatment for 30 days and were reevaluated during a second visit for OSDI scores, TBUT, the Oxford grading scale, and adverse events. Quality of life score were assessed at before and after treatment for 1 month.

03

Conditions studied

  • Dry Eye Disease (DED)
  • Tear Break-Up Time
  • Tear Disorder
  • Tear Film Insufficiency
  • Tear Film Hyperosmolarity
  • Dry Eye
  • Hyaluronate
  • Hyaluronic Acid
  • Corneal Staining
  • Quality of Life

Keywords

  • tear osmolarity
  • artificial tears
  • oxford grading scale
  • DEQS-TH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age more than or equal 18 year-old
  • Ocular Surface Disease Index (OSDI) more than or equal 23
  • Oxford grading scale more than or equal 2 (both eye)
  • Fluorescein tear break-up time less than 7 seconds (both eyes)
  • Willing to being a subject in research.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with other eye diseases that require medication which is not used to treat dry eye, such as Glaucoma
  • History of Ocular surgery in previous 3 months or Refractive surgery in previous 6 months
  • History of ocular trauma, infection, ocular inflammation which is not involved with dry eye in previous 3 months
  • Wear contact lenses
  • Allergic to Sodium hyaluronate
  • Pregnant or lactation period
  • Diagnosed with physical diseases that affect the eyes and cannot yet be controlled, such as uncontrolled DM (Diabetes Mellitus), active disease, and systemic neuropathy induced neurotrophic keratopathy. - Continuous use of medications for diseases such as Retinoic acid derivatives, Antihistamines, Cholinergic agents, and Antipsychotic agents which can lead to chronic dry eye
  • Incompleted data.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Vismax

    0.28% Sodium Hyaluronate , preservative free eye drops

    Drug: 0.28% Sodium Hyaluronate , preservative free eye drops

  • Active comparator
    Vislube

    0.18% Sodium Hyaluronate , preservative free eye drops

    Drug: 0.18% Sodium Hyaluronate , preservative free eye drops

Interventions

  • Drug0.28% Sodium Hyaluronate , preservative free eye drops

    0.28% Sodium Hyaluronate , preservative free eye drops

  • Drug0.18% Sodium Hyaluronate , preservative free eye drops

    0.18% Sodium Hyaluronate , preservative free eye drops

06

What researchers measure

Primary outcomes

  1. To examine the effect of 0.28% Sodium Hyaluronate on corneal epithelial healing

    The Oxford grading scale was used. This scale consists of six levels: 0, I, II, III, IV, and V, with higher values indicating more severe punctate epithelial erosion.

    Time frame: 30 days

  2. To examine the effect of 0.28% Sodium Hyaluronate on reducing tear osmolarity

    Tear osmolarity was monitored before and after the intervention in both arms. Abnormal Tear Osmolarity is defined as a value of ≥ 308 mOsmol/L, measured using the TearLab® system.

    Time frame: 60 minutes

Secondary outcomes

  1. 3. To study the stability of the tear film following the administration of 0.28% Sodium Hyaluronate

    Fluorescein Tear Break-Up Time (FTBUT) was measured in seconds. Abnormal values are defined as a tear break-up time of ≥ 10 seconds.

    Time frame: 0 minutes, 60 minutes, and 30 days.

  2. To assess dry eye symptoms following the administration of 0.28% Sodium Hyaluronate

    The Ocular Surface Disease Index (OSDI) was used. The final score is calculated on a scale from 0 to 100, with higher scores indicating greater severity of ocular surface dysfunction.

    Time frame: 0 minutes and 30 days.

  3. To assess quality of life following the administration of 0.28% Sodium Hyaluronate

    The Dry Eye-Related Quality of Life Score (DEQS-Th) was used. The final score is calculated on a scale from 0 to 100, with higher scores indicating greater severity of ocular surface dysfunction.

    Time frame: 0 minutes and 30 days.

07

Study locations

1 site
  • Rajavithi Hospital, 2, Phayathai Road, Ratchathewi District
    Bangkok, 10400, Thailand
08

References and documents

Publications

  • Tansanguan S, Tananuvat N, Wongpakaran N, Wongpakaran T, Ausayakhun S. Thai version of the dry eye-related quality-of-life score questionnaire: preliminary assessment for psychometric properties. BMC Ophthalmol. 2021 Aug 28;21(1):310. doi: 10.1186/s12886-021-02077-0. PubMed 34454466 ↗
  • Pattanaphesaj J, Thavorncharoensap M, Ramos-Goni JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y. The EQ-5D-5L Valuation study in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):551-558. doi: 10.1080/14737167.2018.1494574. Epub 2018 Jul 6. PubMed 29958008 ↗
  • Prabhasawat P, Tesavibul N, Kasetsuwan N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br J Ophthalmol. 2007 Jan;91(1):47-50. doi: 10.1136/bjo.2006.097691. Epub 2006 Sep 14. PubMed 16973668 ↗
  • Troiano P, Monaco G. Effect of hypotonic 0.4% hyaluronic acid drops in dry eye patients: a cross-over study. Cornea. 2008 Dec;27(10):1126-30. doi: 10.1097/ICO.0b013e318180e55c. PubMed 19034126 ↗
  • Park Y, Song JS, Choi CY, Yoon KC, Lee HK, Kim HS. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye. J Ocul Pharmacol Ther. 2017 Mar;33(2):66-72. doi: 10.1089/jop.2016.0086. Epub 2016 Dec 8. PubMed 27929721 ↗
  • You IC, Li Y, Jin R, Ahn M, Choi W, Yoon KC. Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye. J Ocul Pharmacol Ther. 2018 Oct;34(8):557-564. doi: 10.1089/jop.2018.0032. Epub 2018 Jul 23. PubMed 30036099 ↗
  • Salzillo R, Schiraldi C, Corsuto L, D'Agostino A, Filosa R, De Rosa M, La Gatta A. Optimization of hyaluronan-based eye drop formulations. Carbohydr Polym. 2016 Nov 20;153:275-283. doi: 10.1016/j.carbpol.2016.07.106. Epub 2016 Jul 29. PubMed 27561497 ↗
  • Ang BCH, Sng JJ, Wang PXH, Htoon HM, Tong LHT. Sodium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. Sci Rep. 2017 Aug 21;7(1):9013. doi: 10.1038/s41598-017-08534-5. PubMed 28827614 ↗
  • Lopez-de la Rosa A, Pinto-Fraga J, Blazquez Arauzo F, Urbano Rodriguez R, Gonzalez-Garcia MJ. Safety and Efficacy of an Artificial Tear Containing 0.3% Hyaluronic Acid in the Management of Moderate-to-Severe Dry Eye Disease. Eye Contact Lens. 2017 Nov;43(6):383-388. doi: 10.1097/ICL.0000000000000284. PubMed 27243353 ↗
  • Moschos MM, Chatziralli IP, Sergentanis TN. Viscoat versus Visthesia during phacoemulsification cataract surgery: corneal and foveal changes. BMC Ophthalmol. 2011 Apr 29;11:9. doi: 10.1186/1471-2415-11-9. PubMed 21529354 ↗
  • Balazs EA. Hyaluronan as an ophthalmic viscoelastic device. Curr Pharm Biotechnol. 2008 Aug;9(4):236-8. doi: 10.2174/138920108785161596. PubMed 18691081 ↗
  • Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, Tsubota K. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol. 1995 Nov;79(11):1007-11. doi: 10.1136/bjo.79.11.1007. PubMed 8534643 ↗
  • Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, de Paiva CS, Gomes JAP, Hammitt KM, Jones L, Nichols JJ, Nichols KK, Novack GD, Stapleton FJ, Willcox MDP, Wolffsohn JS, Sullivan DA. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017 Oct;15(4):802-812. doi: 10.1016/j.jtos.2017.08.003. Epub 2017 Aug 8. PubMed 28797892 ↗
  • Buchholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, Figueiredo FC. Utility assessment to measure the impact of dry eye disease. Ocul Surf. 2006 Jul;4(3):155-61. doi: 10.1016/s1542-0124(12)70043-5. PubMed 16900272 ↗
  • Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC, Jones L, Craig JP. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017 Jul;15(3):539-574. doi: 10.1016/j.jtos.2017.05.001. Epub 2017 Jul 20. PubMed 28736342 ↗
  • Rolando M, Cantera E, Mencucci R, Rubino P, Aragona P. The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board. Int Ophthalmol. 2018 Apr;38(2):875-895. doi: 10.1007/s10792-017-0524-4. Epub 2017 Apr 10. PubMed 28397148 ↗
  • Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients. Br J Ophthalmol. 2002 Aug;86(8):879-84. doi: 10.1136/bjo.86.8.879. PubMed 12140209 ↗
  • Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997 Jul;242(1):27-33. doi: 10.1046/j.1365-2796.1997.00170.x. PubMed 9260563 ↗
  • Sahai A, Malik P. Dry eye: prevalence and attributable risk factors in a hospital-based population. Indian J Ophthalmol. 2005 Jun;53(2):87-91. doi: 10.4103/0301-4738.16170. PubMed 15976462 ↗
  • Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003 Oct;22(7):640-50. doi: 10.1097/00003226-200310000-00008. PubMed 14508260 ↗
  • Dalzell MD. Dry eye: prevalence, utilization, and economic implications. Manag Care. 2003 Dec;12(12 Suppl):9-13. PubMed 14723108 ↗
  • McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998 Jun;105(6):1114-9. doi: 10.1016/S0161-6420(98)96016-X. PubMed 9627665 ↗
  • Lekhanont K, Rojanaporn D, Chuck RS, Vongthongsri A. Prevalence of dry eye in Bangkok, Thailand. Cornea. 2006 Dec;25(10):1162-7. doi: 10.1097/01.ico.0000244875.92879.1a. PubMed 17172891 ↗

Individual participant data

Plan to share: No — Patient data cannot be disclosed to other researchers because prior consent was not obtained from the patients.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for May 2025, 8 months after the start.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 8 months is below that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 6, 2025
StartActual
Sep 1, 2024
Primary completionEst.
May 26, 2025
CompletionEst.
Jun 26, 2025
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06860659
Lead sponsor
Department of Medical Services Ministry of Public Health of Thailand
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Sep 1, 2024
Primary completion
May 26, 2025 (estimated)
Completion
Jun 26, 2025 (estimated)
Last update
Mar 6, 2025

Study contacts

Pornlada Sunlakaviset, MD.
principal investigator · Department of Medical Services Ministry of Public Health of Thailand

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion